Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction

Executive Summary

Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows

You may also be interested in...



Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now

So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year

Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now

So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year

Do Avandia Benefits Outweigh Risks? AHRQ, Consumer Reports Are Skeptical

An Agency for Healthcare Research & Quality report concluding thiazolidinediones are no more efficacious than metformin could put formulary pressure on the two marketed products in the class -GlaxoSmithKline's Avandia (rosiglitazone) and Lilly/Takeda's Actos (pioglitazone)

Related Content

UsernamePublicRestriction

Register

PS047823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel